{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:19:53Z","timestamp":1794899993145,"version":"4.9.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"32","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,8]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Cancer therapy-induced thrombocytopenia (CTIT) is a frequent complication in cancer treatment, with severe cases posing risks of bleeding and hindering therapeutic progress.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>\n                      A breast cancer patient developed refractory CTIT following multiple lines of chemotherapy. Despite treatment with various thrombopoietic agents, including recombinant human thrombopoietin, eltrombopag, avatrombopag, steroids, and platelet transfusions, platelet counts remained below 50\u2005\u00d7\u200510\n                      <jats:sup>9<\/jats:sup>\n                      \/L, with a nadir of 6\u2005\u00d7\u200510\n                      <jats:sup>9<\/jats:sup>\n                      \/L.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Bone marrow biopsies revealed an absence of megakaryocytes, supporting the diagnosis of CTIT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The patient received 2 doses of romiplostim N01.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>\n                      The romiplostim N01 resulted in a rapid and sustained normalization of platelet counts. Platelet levels were maintained between 251\u2005\u00d7\u200510\n                      <jats:sup>9<\/jats:sup>\n                      \/L and 304\u2005\u00d7\u200510\n                      <jats:sup>9<\/jats:sup>\n                      \/L during follow-up, allowing uninterrupted anticancer therapy and achieving stable disease for the primary tumor.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>Romiplostim N01 effectively managed refractory CTIT in this case, showing rapid and sustained platelet recovery. This case demonstrates the potential of romiplostim N01 as a potential effective treatment for refractory CTIT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000043665","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T19:01:55Z","timestamp":1755198115000},"page":"e43665","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Successful treatment of refractory cancer therapy-induced thrombocytopenia in a breast cancer patient using romiplostim N01: A case report"],"prefix":"10.1097","volume":"104","author":[{"given":"Peng","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Oncology, General Hospital of Southern Theater Command, Guangzhou, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enlai","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Oncology, General Hospital of Southern Theater Command, Guangzhou, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Oncology, General Hospital of Southern Theater Command, Guangzhou, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology, General Hospital of Southern Theater Command, Guangzhou, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1529-393X","authenticated-orcid":false,"given":"Bo","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Oncology, General Hospital of Southern Theater Command, Guangzhou, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"Ling","sequence":"additional","affiliation":[{"name":"School of Chinese Materia Medica, Guangzhou University of Chinese Medicine, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261117","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1182\/bloodadvances.2019000369","article-title":"Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy.","volume":"3","author":"Al-Samkari","year":"2019","journal-title":"Blood Adv"},{"key":"R2-20261117","first-page":"6S8","article-title":"Cancer and thrombosis: new insights to an old problem.","volume":"45","author":"Leiva","year":"2020","journal-title":"J Med Vasc"},{"key":"R3-20261117","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/hematology.2022000374","article-title":"Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem.","volume":"2022","author":"Al-Samkari","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R4-20261117","first-page":"2579","article-title":"Consensus on the clinical diagnosis, treatment and prevention of cancer treatment-induced thrombocytopenia in China (2023 edition) [in Chinese].","volume":"103","year":"2023","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"R5-20261117","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.clbc.2018.02.003","article-title":"Chemotherapy dose intensity and overall survival among patients with advanced breast or ovarian cancer.","volume":"18","author":"Denduluri","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"R6-20261117","first-page":"925","article-title":"Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer.","volume":"28","author":"Crawford","year":"2020","journal-title":"Support Care Cancer"},{"key":"R7-20261117","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.3389\/fimmu.2018.01251","article-title":"Storage-induced platelet apoptosis is a potential risk factor for alloimmunization upon platelet transfusion.","volume":"9","author":"Saris","year":"2018","journal-title":"Front Immunol"},{"key":"R8-20261117","doi-asserted-by":"crossref","first-page":"101139","DOI":"10.1016\/j.blre.2023.101139","article-title":"Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists.","volume":"63","author":"Al-Samkari","year":"2024","journal-title":"Blood Rev"},{"key":"R9-20261117","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2165\/11208260-000000000-00000","article-title":"Romiplostim: a review of its use in immune thrombocytopenia.","volume":"72","author":"Keating","year":"2012","journal-title":"Drugs"},{"key":"R10-20261117","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s40265-019-01159-0","article-title":"Eltrombopag in immune thrombocytopenia, aplastic anemia, and myelodysplastic syndrome: from megakaryopoiesis to immunomodulation.","volume":"79","author":"Fattizzo","year":"2019","journal-title":"Drugs"},{"key":"R11-20261117","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s40265-018-0949-8","article-title":"Avatrombopag: first global approval.","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"R12-20261117","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40265-015-0525-4","article-title":"Lusutrombopag: first global approval.","volume":"76","author":"Kim","year":"2016","journal-title":"Drugs"},{"key":"R13-20261117","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s40265-021-01575-1","article-title":"Hetrombopag: first approval.","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"R14-20261117","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40265-021-01553-7","article-title":"Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists.","volume":"81","author":"Gilreath","year":"2021","journal-title":"Drugs"},{"key":"R15-20261117","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jtha.2023.09.031","article-title":"Management of chemotherapy-induced thrombocytopenia: guidance from the ISTH subcommittee on hemostasis and malignancy.","volume":"22","author":"Soff","year":"2024","journal-title":"J Thromb Haemost"},{"key":"R16-20261117","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1185\/03007995.2010.510051","article-title":"A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin\/paclitaxel for advanced solid tumors.","volume":"26","author":"Kellum","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"R17-20261117","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s12185-017-2319-9","article-title":"Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study.","volume":"106","author":"Winer","year":"2017","journal-title":"Int J Hematol"},{"key":"R18-20261117","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/S2352-3026(22)00001-1","article-title":"Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"9","author":"Al-Samkari","year":"2022","journal-title":"Lancet Haematol"},{"key":"R19-20261117","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1200\/JCO.18.01931","article-title":"Romiplostim treatment of chemotherapy-induced thrombocytopenia.","volume":"37","author":"Soff","year":"2019","journal-title":"J Clin Oncol"},{"key":"R20-20261117","doi-asserted-by":"crossref","first-page":"e12701","DOI":"10.1002\/rth2.12701","article-title":"Romiplostim for chemotherapy-induced thrombocytopenia: efficacy and safety of extended use.","volume":"6","author":"Wilkins","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"R21-20261117","doi-asserted-by":"crossref","first-page":"e1799","DOI":"10.1212\/WNL.0000000000008440","article-title":"Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: the PLATUM trial.","volume":"93","author":"Le Rhun","year":"2019","journal-title":"Neurology"},{"key":"R22-20261117","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3324\/haematol.2020.251900","article-title":"A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies.","volume":"106","author":"Al-Samkari","year":"2021","journal-title":"Haematologica"},{"key":"R23-20261117","doi-asserted-by":"crossref","first-page":"12","DOI":"10.6004\/jnccn.2020.0002","article-title":"NCCN Guidelines insights: hematopoietic growth factors, version 1.2020.","volume":"18","author":"Becker","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"R24-20261117","doi-asserted-by":"crossref","first-page":"e54723","DOI":"10.1371\/journal.pone.0054723","article-title":"High doses of romiplostim induce proliferation and reduce proplatelet formation by human megakaryocytes.","volume":"8","author":"Currao","year":"2013","journal-title":"PLoS One"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000043665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:01:32Z","timestamp":1794898892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000043665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":24,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000043665","relation":{},"ISSN":["1536-5964","0025-7974"],"issn-type":[{"value":"1536-5964","type":"electronic"},{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"assertion":[{"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}